BR112019005969A2 - inibidores seletivos de jak1 inovadores e usos dos mesmos - Google Patents

inibidores seletivos de jak1 inovadores e usos dos mesmos

Info

Publication number
BR112019005969A2
BR112019005969A2 BR112019005969A BR112019005969A BR112019005969A2 BR 112019005969 A2 BR112019005969 A2 BR 112019005969A2 BR 112019005969 A BR112019005969 A BR 112019005969A BR 112019005969 A BR112019005969 A BR 112019005969A BR 112019005969 A2 BR112019005969 A2 BR 112019005969A2
Authority
BR
Brazil
Prior art keywords
innovative
disorders
selective inhibitors
jak1
jak1 selective
Prior art date
Application number
BR112019005969A
Other languages
English (en)
Inventor
Liang Congxin
Original Assignee
Tll Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tll Pharmaceutical Llc filed Critical Tll Pharmaceutical Llc
Publication of BR112019005969A2 publication Critical patent/BR112019005969A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

derivados de 1h-furo[3,2-b]imidazo[4,5-d]piridina que são inibidores seletivos de quinase jak1, úteis no tratamento de distúrbios relacionados às atividades de jak1, tais como doenças ou distúrbios autoimunes, doenças ou distúrbios inflamatórios e doenças ou distúrbios cancerígenos ou neoplásicos.
BR112019005969A 2016-10-03 2017-09-30 inibidores seletivos de jak1 inovadores e usos dos mesmos BR112019005969A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662403660P 2016-10-03 2016-10-03
PCT/US2017/054668 WO2018067422A1 (en) 2016-10-03 2017-09-30 Novel jak1 selective inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112019005969A2 true BR112019005969A2 (pt) 2019-06-18

Family

ID=61831161

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005969A BR112019005969A2 (pt) 2016-10-03 2017-09-30 inibidores seletivos de jak1 inovadores e usos dos mesmos

Country Status (21)

Country Link
US (2) USRE49834E1 (pt)
EP (1) EP3509591B1 (pt)
JP (1) JP7089141B2 (pt)
KR (1) KR102399848B1 (pt)
CN (2) CN108366994B (pt)
AU (3) AU2017339417C1 (pt)
BR (1) BR112019005969A2 (pt)
CA (1) CA3039178A1 (pt)
DK (1) DK3509591T3 (pt)
EA (1) EA201990523A1 (pt)
ES (1) ES2901216T3 (pt)
HK (1) HK1253040A1 (pt)
HR (1) HRP20211965T1 (pt)
HU (1) HUE058120T2 (pt)
IL (3) IL265358B (pt)
MX (1) MX2019003649A (pt)
NZ (1) NZ751284A (pt)
PL (1) PL3509591T3 (pt)
PT (1) PT3509591T (pt)
RS (1) RS62695B1 (pt)
WO (1) WO2018067422A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7839138B2 (en) * 2007-01-29 2010-11-23 Electro Scientific Industries, Inc. Adjustable force electrical contactor
HUE058120T2 (hu) 2016-10-03 2022-07-28 Highlightll Pharmaceutical Hainan Co Ltd Új JAK1-szelektív inhibitorok és alkalmazásuk
WO2018130563A1 (en) 2017-01-11 2018-07-19 Leo Pharma A/S Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
SG11202104321PA (en) 2018-10-31 2021-05-28 Incyte Corp Combination therapy for treatment of hematological diseases
JP2022524997A (ja) 2019-03-05 2022-05-11 インサイト・コーポレイション 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤
EP3941474A2 (en) 2019-03-19 2022-01-26 Incyte Corporation Biomarkers for vitiligo
MX2021014319A (es) * 2019-06-06 2022-01-26 Highlightll Pharmaceutical Hainan Co Ltd Metodo de sintesis del compuesto de furoimidazopiridina, forma de cristal del compuesto de furoimidazopiridina, y forma de cristal de la sal del mismo.
WO2020244349A1 (zh) * 2019-06-06 2020-12-10 广州高瓴制药有限公司 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物
BR112022023550A2 (pt) 2020-05-19 2023-01-03 Bayer Cropscience Ag (tio)amidas azabicíclicas como compostos fungicidas
US20230234945A1 (en) 2020-06-10 2023-07-27 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides
EP4351584A1 (en) * 2021-06-07 2024-04-17 The Regents of the University of California Compositions and methods for treating celiac disease
EP4419101A1 (en) * 2021-09-13 2024-08-28 Hangzhou Highlightll Pharmaceutical Co., Ltd. Methods of treating cns disorders
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
ATE66143T1 (de) 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
AU4800999A (en) 1998-07-28 2000-02-21 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
WO2005085227A1 (en) 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
CN101282974A (zh) * 2005-08-04 2008-10-08 西特里斯药业公司 作为sirtuin调节剂的咪唑并吡啶衍生物
CN102741253A (zh) * 2009-09-29 2012-10-17 艾科睿控股公司 PI3K(δ)选择性抑制剂
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
CA2813437A1 (en) * 2010-10-08 2012-04-12 Abbvie Inc. Furo[3,2-d]pyrimidine compounds
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
MX365311B (es) 2011-08-12 2019-05-29 Nissan Chemical Ind Ltd Compuestos heterocíclicos tricíclicos inhibidores de jak.
CN104918945B (zh) 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
US20150118229A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
EA201692193A1 (ru) * 2014-04-30 2017-07-31 Инсайт Корпорейшн Способы получения ингибитора jak1 и его новых форм
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
HUE058120T2 (hu) 2016-10-03 2022-07-28 Highlightll Pharmaceutical Hainan Co Ltd Új JAK1-szelektív inhibitorok és alkalmazásuk

Also Published As

Publication number Publication date
IL265358B (en) 2022-04-01
IL291267B1 (en) 2023-01-01
ES2901216T3 (es) 2022-03-21
DK3509591T3 (da) 2021-12-20
AU2022201061A1 (en) 2022-03-10
HUE058120T2 (hu) 2022-07-28
AU2022201058A1 (en) 2022-03-10
CN108366994A (zh) 2018-08-03
JP7089141B2 (ja) 2022-06-22
AU2022201061B2 (en) 2023-03-16
US10738060B2 (en) 2020-08-11
CN113214278B (zh) 2022-10-28
IL291265B1 (en) 2023-01-01
IL291267B2 (en) 2023-05-01
IL291265B2 (en) 2023-05-01
RS62695B1 (sr) 2022-01-31
AU2022201058B2 (en) 2023-03-16
NZ751284A (en) 2022-09-30
USRE49834E1 (en) 2024-02-13
IL291267A (en) 2022-05-01
IL265358A (en) 2019-05-30
HRP20211965T1 (hr) 2022-03-18
CN108366994B (zh) 2021-10-01
JP2019537559A (ja) 2019-12-26
IL291265A (en) 2022-05-01
AU2017339417C1 (en) 2022-06-02
CN113214278A (zh) 2021-08-06
HK1253040A1 (zh) 2019-06-06
WO2018067422A1 (en) 2018-04-12
EA201990523A1 (ru) 2019-10-31
AU2017339417B2 (en) 2021-11-18
KR20190057069A (ko) 2019-05-27
EP3509591B1 (en) 2021-11-17
PT3509591T (pt) 2021-12-27
EP3509591A1 (en) 2019-07-17
PL3509591T3 (pl) 2022-01-31
KR102399848B1 (ko) 2022-05-19
EP3509591A4 (en) 2020-03-25
AU2017339417A1 (en) 2019-03-28
MX2019003649A (es) 2019-08-14
US20190256523A1 (en) 2019-08-22
CA3039178A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
BR112019005969A2 (pt) inibidores seletivos de jak1 inovadores e usos dos mesmos
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
EA201691745A1 (ru) Ингибиторы jak1 для лечения миелодиспластических синдромов
MX2019004070A (es) Sistema de extraccion de un sistema de circuito cerrado.
SG11201907095UA (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
EA202090371A1 (ru) 1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
BR112018006135A2 (pt) derivados de pirazol fundidos como inibidores da cinase
EP3515914A4 (en) NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES
PH12016501232A1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
AU2017261291A1 (en) Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
CO2018013803A2 (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
CY1120415T1 (el) Θεραπευτικα δραστικα παραγωγα πυραζολο-πυριμιδινης
BR112015022011A2 (pt) derivados de imidazo[4,5-c]piridina e pirrolo[2,3-c] piridina como inibidores de ssao
UY37559A (es) Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
EA201891897A1 (ru) 1,5-ДИГИДРО-4H-ПИРАЗОЛО[3,4-d]ПИРИМИДИН-4-ОНЫ И 1,5-ДИГИДРО-4H-ПИРАЗОЛО[4,3-c]ПИРИДИН-4-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1
CO2019005538A2 (es) Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1
EP3215510A4 (en) Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
BR112019004992A2 (pt) inibição da sinalização de bmp, compostos, composições e usos destes
BR112018007358A2 (pt) derivados de 1,4-dicarbonil-piperidila
EA201891349A1 (ru) Производные гексагидропиразинотриазинона в качестве ингибиторов киназы
EA201890826A1 (ru) Конденсированные производные пиридина в качестве ингибиторов киназы
EA201892549A1 (ru) ПРИМЕНЕНИЕ 1H-ПИРАЗОЛО[4,3-b]ПИРИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HIGHLIGHTLL PHARMACEUTICAL (USA) LLC (US)

B25A Requested transfer of rights approved

Owner name: HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD (CN)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]